Covered recipient · General Payments record
JOHN D GABRIEL
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$2,687.74
128 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,452.05 | 127 |
| Travel and Lodging | $235.69 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novartis Pharmaceuticals Corporation | $519.37 | 3 |
| AstraZeneca Pharmaceuticals LP | $293.48 | 5 |
| ABBVIE INC. | $233.55 | 14 |
| PFIZER INC. | $218.96 | 15 |
| Abbott Laboratories | $198.94 | 10 |
| Amgen Inc. | $169.17 | 16 |
| GlaxoSmithKline, LLC. | $160.75 | 8 |
| Corium, LLC | $159.22 | 5 |
| Lilly USA, LLC | $144.80 | 17 |
| Tris Pharma Inc | $123.94 | 7 |
| Novo Nordisk Inc | $70.99 | 4 |
| Exact Sciences Corporation | $70.35 | 4 |
| Astellas Pharma US Inc | $62.98 | 4 |
| IDORSIA PHARMACEUTICALS US INC | $61.17 | 4 |
| Verity Pharmaceuticals Inc. | $50.88 | 3 |
| Dexcom, Inc. | $49.09 | 3 |
| Philips North America LLC | $22.92 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.40 | 1 |
| Axsome Therapeutics, Inc. | $16.48 | 1 |
| Merck Sharp & Dohme LLC | $14.46 | 1 |
| Antares Pharma, Inc. | $13.48 | 1 |
| Noven Therapeutics, LLC | $13.36 | 1 |
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN D GABRIEL
NPI 1407844764 · CMS profile ID 200092
Allopathic & Osteopathic Physicians / Family Medicine
NORTH RICHLAND HILLS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1407844764?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN D GABRIEL, NPI 1407844764, CMS profile ID 200092. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407844764?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOHN D GABRIEL, NPI 1407844764, CMS profile ID 200092. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407844764?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOHN D GABRIEL, NPI 1407844764, CMS profile ID 200092, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1407844764?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
128 matching records · $2,687.74 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–128 of 128.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $12.96 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131561965 | CMS |
| Antares Pharma, Inc. | $13.48 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146459159 | CMS |
| Amgen Inc. | $9.69 | 03/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111579117 | CMS |
| PFIZER INC. | $15.08 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131043144 | CMS |
| PFIZER INC. | $0.57 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131538124 | CMS |
| Novo Nordisk Inc | $17.67 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097542466 | CMS |
| Lilly USA, LLC | $17.08 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135070753 | CMS |
| Noven Therapeutics, LLC | $13.36 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1084821977 | CMS |
| Dexcom, Inc. | $19.90 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153309543 | CMS |
| PFIZER INC. | $14.71 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131049343 | CMS |
| Lilly USA, LLC | $5.09 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135070215 | CMS |
| GlaxoSmithKline, LLC. | $18.82 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116693191 | CMS |
| PFIZER INC. | $14.59 | 02/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131027927 | CMS |
| Amgen Inc. | $8.63 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111579115 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.14 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105899276 | CMS |
| Lilly USA, LLC | $3.48 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135067981 | CMS |
| Lilly USA, LLC | $2.23 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135068189 | CMS |
| Corium, LLC | $31.99 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100221971 | CMS |
| ABBVIE INC. | $15.30 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103763092 | CMS |
| Astellas Pharma US Inc | $17.52 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139289606 | CMS |
| GlaxoSmithKline, LLC. | $19.66 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116349356 | CMS |
| Exact Sciences Corporation | $16.80 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114665457 | CMS |
| Tris Pharma Inc | $16.36 | 01/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147219218 | CMS |
| Amgen Inc. | $13.34 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117256055 | CMS |
| Corium, LLC | $34.38 | 01/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100221711 | CMS |
| Abbott Laboratories | $15.81 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125051078 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.59 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105396812 | CMS |
| PFIZER INC. | $15.84 | 01/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130943762 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $851,656.16 | 29 |
| PY2024 | Recipient | $6,094.00 | 2 |
| PY2024 | Principal investigator | $980,465.66 | 23 |
| PY2023 | Recipient | $402.14 | 1 |
| PY2023 | Principal investigator | $1,421,987.77 | 29 |
| PY2022 | Recipient | $37,727.00 | 4 |
| PY2022 | Principal investigator | $1,125,784.81 | 19 |
| PY2021 | Recipient | $779.39 | 2 |
| PY2021 | Principal investigator | $2,812,479.81 | 20 |
| PY2020 | Recipient | $2,073.40 | 3 |
| PY2020 | Principal investigator | $463,650.78 | 6 |
| PY2019 | Principal investigator | $93,620.20 | 16 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
29 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $2,868.36 | 11/05/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202522721 |
| Principal investigator 1 | Ardelyx, Inc. | $11,000.00 | 10/29/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH INC | A 26-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Chronic Idiopathic Constipation (CIC) in Adults | No dispute reported | 06/30/2026 | 1247838761 |
| Principal investigator 1 | ABBVIE INC. | $1,840.08 | 10/09/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202515811 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,172.36 | 09/18/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190308816 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,157.72 | 09/11/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190308810 |
| Principal investigator 1 | ABBVIE INC. | $1,614.36 | 09/04/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202509240 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,255.55 | 08/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190308484 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $84,281.77 | 08/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190308812 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $66,229.21 | 08/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190308814 |
| Principal investigator 1 | ABBVIE INC. | $2,882.88 | 08/06/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202503161 |
| Principal investigator 1 | ABBVIE INC. | $1,987.92 | 07/02/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202494961 |
| Principal investigator 1 | ABBVIE INC. | $645.48 | 07/02/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202494963 |
| Principal investigator 1 | Eli Lilly and Company | $222,423.00 | 06/24/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187889252 |
| Principal investigator 1 | ABBVIE INC. | $1,533.84 | 06/03/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202488973 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,071.63 | 06/02/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD | No dispute reported | 06/30/2026 | 1190306029 |
| Principal investigator 1 | Eli Lilly and Company | $450.00 | 05/19/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) | No dispute reported | 06/30/2026 | 1187886478 |
| Principal investigator 1 | ABBVIE INC. | $3,148.20 | 05/07/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202483387 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,100.00 | 05/07/2025 | Non-covered Recipient Entity NORTH HILLS MED RESEARCH INC | A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Polymyositis | No dispute reported | 06/30/2026 | 1185541494 |
| Principal investigator 1 | Eli Lilly and Company | $13,715.39 | 04/22/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 | No dispute reported | 06/30/2026 | 1187887664 |
| Principal investigator 1 | ABBVIE INC. | $9,988.44 | 04/03/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202471804 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,424.51 | 03/07/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients | No dispute reported | 06/30/2026 | 1190306025 |
| Principal investigator 1 | ABBVIE INC. | $3,863.64 | 02/06/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202448989 |
| Principal investigator 1 | Eli Lilly and Company | $878.40 | 01/27/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187886894 |
| Principal investigator 1 | Eli Lilly and Company | $337.50 | 01/27/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187889250 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,474.93 | 01/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190306021 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $109,085.20 | 01/21/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190306023 |
| Principal investigator 1 | Eli Lilly and Company | $73,635.00 | 01/07/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187886892 |
| Principal investigator 1 | Eli Lilly and Company | $96,089.00 | 01/07/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187887662 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,501.79 | 01/07/2025 | Non-covered Recipient Entity NORTH HILLS MEDICAL RESEARCH, INC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190306027 |